Entecavir Hydrate (Synonyms: BMS 200475, SQ 34,676) |
| カタログ番号GC16092 |
エンテカビル水和物 (BMS200475 一水和物; SQ34676 一水和物) は、HepG2 細胞での EC50 が 3.75 nM の HBV の強力かつ選択的な阻害剤です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 209216-23-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Entecavir hydrate is a reverse transcriptase inhibitor.
Reverse transcriptase (RT) is used to generate complementary DNA (cDNA) from an RNA template, which is mainly associated with retroviruses, such as HBV.
Entecavir hydrate is an oral antiviral drug used in the treatment of hepatitis B virus (HBV) infection. In 17 patients with hepatitis B virus (HBV) genotype C, treatment with peginterferon
(PEG-IFN) a-2b combination with entecavir hydrate (ETV) for 48 weeks. Among 11 patients exhibited pretherapy HBeAg, 8 showed HBeAg seroconversion. Serum HBV DNA levels reduced by 5.2 and 3.3 log copies/ml by the end of the therapy and follow-up periods, respectively. Intrahepatic cccDNA reduced to 1.4 log copies/mg.
References:
[1]. Hagiwara S, Kudo M, Osaki Y, et al. Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. J Med Virol, 2013, 85(6): 987-995.
Average Rating: 5 (Based on Reviews and 39 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *